Explore major changes in healthcare insurance for 2025, including drug pricing, Medicaid adjustments, and the role of AI in transforming risk management.

Key regulatory and legislative developments shaping U.S. healthcare and insurance in late 2025, including APTC expirations, CMS innovations, FDA initiatives, and congressional healthcare policy efforts.

Explore how high-cost gene therapies like Zolgensma are affecting U.S. employer-sponsored insurance and healthcare coverage amid rising costs and manufacturing challenges.

The U.S. federal government has paid $16 billion to Medicare Part D insurers due to rising prescription drug spending, highlighting cost and risk management challenges in Medicare drug plans.

Eli Lilly's diabetes drug Mounjaro is set to be included in China's national health insurance reimbursement list, boosting accessibility but with potential revenue impact from pricing adjustments.

Eli Lilly's Mounjaro joins China's national health insurance list for type 2 diabetes, enhancing accessibility amid pricing adjustments. Related diabetes therapies and market impacts examined.

China launches its first Commercial Health Insurance Innovative Drug List with CAR-T therapies, advancing access to innovative cancer and rare disease treatments under commercial insurance.

CMS expands Medicare drug price controls to 25 medications, achieving $12 billion savings with new Maximum Fair Prices starting 2026 and 2027 for chronic and cancer treatments.

CMS announces $12 billion savings from Medicare drug price negotiations on 15 high-cost medications, effective 2027, enhancing Medicare Part D sustainability.

The FDA has reassigned the director of its Office of Nonprescription Drugs to a medical devices leadership role, highlighting a strategic shift toward affordability and regulatory realignment. This change may impact drug approval policies and insurance regulatory compliance.